A Multicenter Randomized Controlled Study of Photoelectric Detection in Cervical Cancer Screening

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorLei Li

About this trial

The main purpose of this study is to verify the accuracy of the fluorescence photoelectric cervical lesion image detector relative to the pathological gold standard and the detection rate of CIN 2 +, as well as the significance of it as a shunt tool before colposcopy through a randomized controlled study.

The secondary objectives were to compare the relative pathological accuracy of the fluorescence photoelectric cervical lesion image detection results with the HPV detection results and cytological results, and to compare the lesion area displayed by the fluorescence photoelectric cervical lesion image detector with the lesion area that appeared after traditional colposcopy chemical staining.

In this study, 4200 subjects who have been evaluated and can be enrolled (these subjects have the indication of referral to colposcopy) will be included in the study, and they will be divided into two groups according to the principle of randomization. The histological results were obtained after routine colposcopy and biopsy. The experimental group first underwent colposcopy and biopsy after the judgment of the fluorescent photoelectric cervical lesion image detector to obtain histological results. Finally, the accuracy of the relative pathological results, the detection rate of CIN2 +, negative predictive value and positive predictive value of the two groups were compared.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Age ≥ 18 years old, ≤ 65 years old, with a complete cervix without deformity.

2. Have clear cervical cancer screening results, meet HPV16/18 (+) or high-risk HPV (+), and cervical cytology results ≥ ASC-US.

3. Fully informed and agreed to participate in the study.

4. No history of cervical cancer disease and cancer in other parts.

Disqualifiers

1. Cannot meet all Inclusion Criteria.

2. There is clear immunosuppression, such as HIV infection or organ transplantation, etc., and the vagina or cervix is in the acute inflammation stage。

3. There are serious bleeding diseases or photosensitive diseases such as abnormal coagulation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Detection of Cervical Lesions by Fluorescence Photoelectric Image

    Diagnostic test

    Photoelectric detection was carried out on the subjects of the experimental group.

Treatment groups

4,200 Participants
are divided into 2 treatment groups
Group A: Group Accepting Photoelectric DetectionExperimental treatment 1 intervention
Group B: Routine colposcopy groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Sensitivity and specificity of a fluorescence photoelectric image detector for cervical lesions.

Sensitivity and specificity of the fluorescence photoelectric detection technique relative to histopathological findings.

Time frame
Enrolled subjects receive histopathological results approximately 7 days after colposcopy.
2

Detection rate of CIN2+ by fluorescence photoelectric cervical lesion image detector.

The sensitivity, specificity, CIN2+ detection rate, negative predictive value and positive predictive value were compared between the fluorescence photoelectric technology and HPV detection results and cytology results, and the consistency and coincidence between the fluorescence photoelectric technology and HPV detection results and cytology results were calculated.

Time frame
Enrolled subjects receive histopathological results approximately 7 days after colposcopy.

Secondary outcomes

1

The correlation between fluorescence photoelectric technology and HPV detection and cytology results.

The sensitivity, specificity, CIN2+ detection rate, negative predictive value and positive predictive value were compared with the results of HPV detection and cytology.

Time frame
Enrolled subjects receive histopathological results approximately 7 days after colposcopy.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Lei Li

Lead sponsor

Peking Union Medical College Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: